Medivir AB Signs Agreement with Daewoong Pharmaceutical Co., Ltd. to Distribute Xerclear(R) in China and Hong Kong
HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIRB), a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir’s unique cold sore treatment Xerclear® in China and Hong Kong.